On November 3, 2026, Australia's Therapeutic Goods Administration (TGA) registered Wegovy (semaglutide) tablets on the Australian Register of Therapeutic Goods (ARTG). The registration covers four tablet strengths: 1.5 mg, 4 mg, 9 mg, and 25 mg. The sponsor is Novo Nordisk Pharmaceuticals Pty Ltd.
Key Points
- Registration date: November 3, 2026, on the Australian Register of Therapeutic Goods.
- Tablet strengths: 1.5 mg, 4 mg, 9 mg, and 25 mg.
- Launch date: No Australian launch date has been announced.
- Price: No Australian price has been announced.
What the TGA registered
The TGA added four Wegovy tablet entries to the ARTG on November 3, 2026, one for each strength. The 1.5 mg entry (ARTG ID 522753) records the registration date as November 3, 2026, lists semaglutide as the active ingredient, and names Novo Nordisk Pharmaceuticals Pty Ltd as sponsor. The 4 mg, 9 mg, and 25 mg tablets were registered the same day.
The registration covers chronic weight management in eligible adults and reducing the risk of major adverse cardiovascular events. The 25 mg tablet's indication covers adults with obesity (BMI of 30 or higher) or adults who are overweight (BMI of 27 or higher) with at least one weight-related health condition, alongside reduced-energy eating and increased physical activity. The tablets are prescription-only. Dosing follows the Australian Product Information and the prescriber's directions.
This is the first oral GLP-1 medicine registered in Australia specifically for weight management. Australia already has an oral semaglutide medicine, Rybelsus, but it is registered for type 2 diabetes, not weight management.
The weekly GLP-1 email
Plain-English answers on side effects, eating, cost and the newest medications. Free, one email a week.
No launch date or price yet
No Australian launch date or price has been announced. Novo Nordisk has said it is working toward making the tablets available in Australia later in 2026, and Australian news reports on November 3 said the pill was expected before Christmas, but that is an expectation, not a confirmed date. Diabetes Australia said on November 6, 2026, that further product and packaging work was needed and that the Australian launch date and price were still to be confirmed. Registration alone does not mean the tablets are stocked in pharmacies.
No Pharmaceutical Benefits Scheme (PBS) listing for oral Wegovy for weight management has been announced, so patients should expect to pay the private price when the tablets reach pharmacies. The TGA has also warned Australians about fake and unregistered weight-loss medicines sold online.
The evidence behind the tablet
The 25 mg dose was studied in the OASIS 4 phase 3 trial, published in the New England Journal of Medicine in September 2025. The trial enrolled 307 adults without diabetes who had obesity or overweight with at least one health condition, and compared the tablet with a placebo. It did not compare the tablet with Wegovy injections.
In the United States, the Wegovy pill was approved by the FDA in December 2025 and launched in January 2026. US pricing is not Australian pricing: in the US, NovoCare lists self-pay prices starting at $149 a month for the 1.5 mg tablet. See our Wegovy pill cost guide for the US figures. No Australian price has been announced.
Sources: TGA, ARTG entry 522753 — Wegovy semaglutide 1.5 mg tablet, registered November 3, 2026; The Nightly, November 3, 2026; Aesthetic Medical Practitioner, November 2026.

